Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Randox Laboratories Ltd.. (4/21/18). "Press Release: Randox / Bosch Partnership Delivers Game-changing Device in Fight against Antibiotic Resistance".

Organisations Organisation Randox Laboratories Ltd.
  Group Randox (Group)
  Organisation 2 Bosch Healthcare Solutions GmbH
  Group Bosch (Group)
Products Product Vivalytic point-of-care analyser
  Product 2 Biochip Array Technology (Randox)
Index term Index term Bosch–Randox: point-of-care diagnostics, –201804 collab developm test panels for Vivalytic POC analyser
Persons Person FitzGerald, Peter (Randox Laboratories 200710 Managing Director)
  Person 2 Meier, Marc (Bosch 201804 General Manager of Bosch Healthcare Solutions)
     


A partnership between Randox Laboratories, the UK’s largest manufacturer of in-vitro diagnostics, and the German technology giant Bosch is changing the way doctors will treat patients with antibiotics, with the launch of a revolutionary product – the Vivalytic.

It’s estimated that 20% of antibiotics currently prescribed are unnecessary, and fuel the growing threat of global antibiotic resistance. This threatens the ability to treat common infectious diseases, and a growing number are becoming harder, and in some cases impossible, to treat. The World Health Organisation warns that without action, we are heading towards a post-antibiotic era.

This problem is being addressed by the Vivalytic. The result of a decade of R&D, it is an intuitive point-of-care analyser that, depending on the complexity of the test, will deliver results from 30 minutes: enabling doctors to select the right course of therapy faster than before. In some cases, this will be life-saving.

The first tests available on the Vivalytic are Randox’s panels for respiratory and sexually-transmitted infections*.

Using Randox’s patented Biochip Array Technology, the Respiratory Multiplex Array simultaneously reports on 22 viral and bacterial pathogens including Bordetella pertussis and parapertussis which causes whooping cough – without the need for secondary or confirmatory testing to inform clinical treatment decisions. The STI array enables the detection of 10 STIs from a single sample. Every day more than 1 million STIs are acquired, and many have mild if any symptoms at all. Identifying these infections correctly first time reduces the misuse of antibiotics and supports their targeted use.

The Managing Director of Randox Dr Peter FitzGerald commented:

“Antibiotic stewardship is a critical issue which we all have a responsibility to embrace and drive forward. This partnership is ideal, combining our expertise in molecular laboratory diagnostics with Bosch’s cutting-edge engineering. The Vivalytic is a game-changer for clinicians and patients: never before has there been this level of accessibility to this range of molecular diagnostics.”

Marc Meier, General Manager of Bosch Healthcare Solutions, a wholly owned subsidiary of Bosch Group, said:

“We are enthusiastic about having gained Randox as the first partner on our platform with two initial panels available from the start. It´s the beginning of jointly expanding the Vivalytic test portfolio for our clients. In this partnership the core competencies of Bosch in automation, miniaturization, and networking are complemented by Randox’s expertise in developing and commercializing innovative diagnostic solutions.”

Vivalytic and the panels will be presented to industry professionals for the first time at the ECCMID 2018 Congress in Madrid, Spain, in hall 10, booth 55A between 21st – 24th April.


* CE pending and FDA planned.


For further information about the Vivalytic, please contact randoxpr@randox.com

   
Record changed: 2018-11-15

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Randox (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top